Controversies in proliferative vitreoretinopathy tamponade and pharmacologic adjuvants

International Ophthalmology Clinics

Volumn 45, Issue 4, 2005, Pages 163-171

  Young, Tara A ^a   D'Amico, Donald J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACRYLIC ACID METHYL ESTER; ALKANE; ANTINEOPLASTIC AGENT; COLLAGEN; COPOLYMER; CORTICOSTEROID; FLUOROCARBON; FLUOROSILICONE; FLUOROURACIL; HYALURONIC ACID; HYDROXYPROPYLMETHYLCELLULOSE; LOW MOLECULAR WEIGHT HEPARIN; POLY(METHYLACRYLAMIDOGLYCOLATE METHYL ESTER); POLYVINYL ALCOHOL; POVIDONE IODINE; RETINOIC ACID; SILICONE GEL; SILICONE OIL; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA DETACHMENT SURGERY; REVIEW; SCLERA BUCKLING PROCEDURE; SURGICAL TECHNIQUE; VITRECTOMY; VITREORETINOPATHY; WOUND HEALING;

ADJUVANTS, PHARMACEUTIC; FLUOROCARBONS; HUMANS; MACROMOLECULAR SUBSTANCES; RETINAL DETACHMENT; SILICONE OILS; SULFUR HEXAFLUORIDE; VITRECTOMY; VITREORETINOPATHY, PROLIFERATIVE;

EID: 27544445307     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.iio.0000176368.93887.2c     Document Type: Review

References (47)

1. Hilton G, Machemer R, Michels R, et al. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology. 1983;90:121-125.
2. Rachal WF, Burton TC. Changing concepts of failures after retinal detachment surgery. Arch Ophthalmol. 1979;97:480-483.
3. Machemer R, Aaberg TM, Freeman HM, et al. An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol. 1991;112:159-165.
4. Singh AK, Glaser BM, Lemor M, et al. Gravity-dependent distribution of retinal pigment epithelial cells dispersed into the vitreous cavity. Retina. 1986;6:77-80.
5. Asaria RH, Kon CH, Bunce C, et al. How to predict proliferative vitreoretinopathy: a prospective study. Ophthalmology. 2001;108:1184-1186.
6. Nagasaki H, Shinagawa K, Mochizuki M. Risk factors for proliferative vitreoretinopathy. Prog Retin Eye Res. 1998;17:77-98.
7. Pastor JC, de la Rua ER, Martin F. Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res. 2002;21:127-144.
8. Cox MS, Trese MT, Murphy PL. Silicone oil for advanced proliferative vitreoretinopathy. Ophthalmology. 1986;93:646-650.
9. Parke DW II, Aaberg TM. Intraocular argon laser photocoagulation in the management of severe proliferative vitreoretinopathy. Am J Ophthalmol. 1984;97:434-443.
10. Sell CH, McCuen BW II, Landers MB III, et al. Long-term results of successful vitrectomy with silicone oil for advanced proliferative vitreoretinopathy. Am J Ophthalmol. 1987;103:24-28.
11. Sternberg P Jr, Machemer R. Results of conventional vitreous surgery for proliferative vitreoretinopathy. Am J Ophthalmol 1985;100:141-146.
12. Chang S. Intraocular gases. In: Ryan SJ, ed. Retina. St. Louis: Mosby, Inc; 2001:2147-2161.
13. Fu AD, McDonald HR, Eliott D, et al. Complications of general anesthesia using nitrous oxide in eyes with preexisting gas bubbles. Retina. 2002;22:569-574.
14. Krzystolik MG, D'Amico DJ. Complications of intraocular tamponade: silicone oil versus intraocular gas. Int Ophthalmol Clin. 2000;40:187-200.
15. Scott IU, Flynn HW Jr, Murray TG, et al. Outcomes of surgery for retinal detachment associated with proliferative vitreoretinopathy using perfluoro-n-octane: a multicenter study. Am J Ophthalmol. 2003;136:454-463.
16. Orzalesi N, Migliavacca L, Bottoni F, et al. Experimental short-term tolerance to perfluorodecalin in the rabbit eye: a histopathological study. Curr Eye Res. 1998;17:828-835.
17. Kirchhof B, Wong D, Van Meurs J, et al. Use of perfluorohexyloctane as a long-term internal tamponade agent in complicated retinal detachment surgery. Am J Ophthalmol. 2002;133:95-101.
18. Kobuch K, Menz IH, Hoerauf H, et al. New substances for intraocular tamponades: perfluorocarbon liquids, hydrofluorocarbon liquids and hydrofluorocarbon-oligomers in vitreoretinal surgery. Graefes Arch Clin Exp Ophthalmol. 2001;239:635-642.
19. Vote B, Wheen L, Cluroe A, et al. Further evidence for proinflammatory nature of perfluorohexyloctane in the eye. Clin Exp Ophthalmol. 2003;31:408-414.
20. Petersen J. The physical and surgical aspects of silicone oil in the vitreous cavity. Graefes Arch Clin Exp Ophthalmol. 1987;225:452-456.
21. Abu El-Asrar AM, Al-Bishi SM, Kangave D. Outcome of temporary silicone oil tamponade in complex rhegmatogenous retinal detachment. Eur J Ophthalmol. 2003;13:474-481.
22. Dalton PD, Jefferson A, Hong Y, et al. The use of Fourier transform infrared spectrometry for monitoring the retention of polymers in the vitreous humour. Biomed Mater Eng. 1995;5:185-193.
23. Doi M, Refojo MF. Histopathology of rabbit eyes with intravitreous silicone-fluorosilicone copolymer oil. Exp Eye Res. 1994;59:737-746.
24. Doi M, Refojo MF. Histopathology of rabbit eyes with silicone- fluorosilicone copolymer oil as six months internal retinal tamponade. Exp Eye Res. 1995;61:469-478.
25. Fernandez-Vigo J, Refojo MF, Verstraeten T. Evaluation of a viscoelastic solution of hydroxypropyl methylcellulose as a potential vitreous substitute. Retina. 1990;10:148-152.
26. Giordano GG, Refojo MF. Silicone oils as vitreous substitutes. Prog Polym Sci 1998;23:509-532.
27. Hong Y, Chirila TV, Cuypers MJ, et al. Polymers of 1-vinyl-2- pyrrolidinone as potential vitreous substitutes: physical selection. J Biomater Appl. 1996;11:135-181.
28. Hong Y, Chirila TV, Fitton JH, et al. Effect of crosslinked poly (1-vinyl-2-pyrrolidinone) gels on cell growth in static cell cultures. Biomed Mater Eng. 1997;7:35-47.
29. Hong Y, Chirila TV, Vijayasekaran S, et al. Crosslinked poly(1-vinyl-2-pyrrolidinone) as a vitreous substitute. J Biomed Mater Res. 1996;30:441-448.
30. Hong Y, Chirila TV, Vijayasekaran S, et al. Biodegradation in vitro and retention in the rabbit eye of crosslinked poly(1-vinyl-2-pyrrolidinone) hydrogel as a vitreous substitute. J Biomed Mater Res. 1998;39:650-659.
31. Liang C, Peyman GA, Serracarbassa P, et al. An evaluation of methylated collagen as a substitute for vitreous and aqueous humor. Int Ophthalmol. 1998;22:13-18.
32. Nakagawa M, Tanaka M, Miyata T. Evaluation of collagen gel and hyaluronic acid as vitreous substitutes. Ophthalmic Res. 1997;29:409-420.
33. Peyman GA, Conway MD, Karacorlu M, et al. Evaluation of silicone gel as a long-term vitreous substitute in non-human primates. Ophthalmic Surg. 1992;23:811-817.
34. Peyman GA, Schulman JA, Sullivan B. Perfluorocarbon liquids in ophthalmology. Surv Ophthalmol. 1995;39:375-395.
35. Bottoni F, Sborgia M, Arpa P, et al. Perfluorocarbon liquids as postoperative short-term vitreous substitutes in complicated retinal detachment. Graefes Arch Clin Exp Ophthalmol. 1993;231:619-628.
36. Eckardt C, Nicolai U, Winter M, et al. Experimental intraocular tolerance to liquid perfluorooctane and perfluoropolyether. Retina. 1991;11:375-384.
37. Stefaniotou MI, Aspiotis MV, Kitsos GD, et al. Our experience with perfluorohexyloctane (F6H8) as a temporary endotamponade in vitreoretinal surgery. Eur J Ophthalmol. 2002;12:518-522.
38. Hiscott P, Magee RM, Colthurst M, et al. Clinicopathological correlation of epiretinal membranes and posterior lens opacification following perfluorohexyloctane tamponade. Br J Ophthalmol. 2001;85:179-183.
39. Abrams GW, Azen SP, McCuen BW II, et al. Vitrectomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy: results of additional and long-term follow-up. Silicone Study report 11. Arch Ophthalmol. 1997;115:335-344.
40. Afrashi F, Erakgun T, Akkin C, et al. Conventional buckling surgery or primary vitrectomy with silicone oil tamponade in rhegmatogenous retinal detachment with multiple breaks. Graefes Arch Clin Exp Ophthalmol. 2004;242:295-300.
41. Scott IU, Flynn HW Jr, Azen SP, et al. Silicone oil in the repair of pediatric complex retinal detachments: a prospective, observational, multicenter study. Ophthalmology. 1999;106:1399-1407; discussion 1407-1408.
42. Schulman JA, Peyman GA. Intracameral, intravitreal and retinal drug delivery. In: Mitra AK, ed. Ophthalmic Drug Delivery Systems. New York: Marcel Dekker; 1993:383-425.
43. Pastor JC. Proliferative vitreoretinopathy: an overview. Surv Ophthalmol. 1998;43:3-18.
44. Iverson DA, Katsura H, Hartzer MK, et al. Inhibition of intraocular fibrin formation following infusion of low-molecular-weight heparin during vitrectomy. Arch Ophthalmol. 1991;109:405-409.
45. Asaria RH, Kon CH, Bunce C, et al. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial. Ophthalmology. 2001;108:1179-1183.
46. Kon CH, Occleston NL, Foss A, et al. Effects of single, short-term exposures of human retinal pigment epithelial cells to thiotepa or 5-fluorouracil: implications for the treatment of proliferative vitreoretinopathy. Br J Ophthalmol. 1998;82:554-560.
47. Araiz JJ, Refojo MF, Arroyo MH, et al. Antiproliferative effect of retinoic acid in intravitreous silicone oil in an animal model of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1993;34:522-530.